Location History:
- Taunusstein-Wehen, DE (1980)
- Taunusstein, DE (1985)
Company Filing History:
Years Active: 1980-1985
Title: Klaus Gleixner: Pioneering Innovations in Pharmaceutical Compositions
Introduction
Klaus Gleixner is a notable inventor based in Taunusstein-Wehen, Germany, recognized for his contributions to the field of pharmaceutical compositions. With a strong focus on innovative solutions for medications, Gleixner has successfully secured two patents that highlight his expertise and commitment to improving patient care.
Latest Patents
Gleixner's latest patents include groundbreaking formulations designed to enhance the tolerability of certain medications. One significant patent details a pharmaceutical composition of xanthine derivatives, specifically formulated to be well tolerated by the stomach. This composition comprises a mixture of granules coated with a gastric juice-resistant material, along with a portion of up to 30% of granules that are soluble or partially soluble in gastric juice. Another patent further elaborates on pharmaceutical compositions for oral administration in dosage unit form, incorporating at least one xanthine derivative from a specific group. These innovations reflect Gleixner's dedication to developing medicines that are easier on the digestive system, ultimately benefiting patients.
Career Highlights
Klaus Gleixner has made significant strides in his career, working with Hoechst Aktiengesellschaft, a prominent company known for its research and development in pharmaceutical sciences. His role in the company has allowed him to leverage his inventive skills to create practical solutions that can be utilized in various medical applications. This environment has fostered his talent for innovation and reinforced his position as a key player in the pharmaceutical industry.
Collaborations
Throughout his career, Gleixner has collaborated with other esteemed professionals, including colleagues like Roland Muller and Franz Lehrach. These partnerships not only enhance the innovative output but also contribute to a collaborative atmosphere where ideas can flourish. By working in tandem with other skilled inventors and researchers, Gleixner has been able to bring his inventive concepts to fruition, thus furthering the advancement of pharmaceutical sciences.
Conclusion
Klaus Gleixner exemplifies the spirit of innovation in the pharmaceutical industry through his inventive mind and impactful patents. His work with xanthine derivatives and the focus on patient tolerability demonstrate his commitment to improving medication efficacy and safety. As the field of pharmaceuticals continues to evolve, inventors like Gleixner play a crucial role in pioneering solutions that meet the medical needs of society.